Brought to you by 
Abbott, Karo Bio develop Type II diabetes drugs; ended
21 Oct 2004
Executive Summary
Abbott Laboratories and Swedish pharmaceutical Karo Bio AB signed a three-year deal to develop Type II diabetes therapeutics. Abbott will use Karo Bio's nuclear receptor technology and potential drug candidates, and the partners will together handle research and preclinical development.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abbott, Karo Bio develop Type II diabetes drugs; ended
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice